KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors

@inproceedings{GarridoLaguna2012KRASnessAP,
  title={KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors},
  author={Ignacio Garrido-Laguna and David S. Hong and Filip Janku and Ly Minh Nguyen and Gerald Steven Falchook and S. Kristine Fu and Jenifer J. Wheler and Rajyalakshmi Luthra and Aung S. Naing and Xuemei Wang and Razelle Kurzrock},
  booktitle={PloS one},
  year={2012}
}
PURPOSE To evaluate clinicopathologic and molecular features of patients with metastatic colorectal cancer (mCRC) and their outcomes in early-phase trials using pathway-targeting agents. PATIENTS AND METHODS We analyzed characteristics of 238 patients with mCRC referred to the phase 1 trials unit at MD Anderson Cancer Center. KRAS, PIK3CA and BRAF status were tested using PCR-based DNA sequencing. RESULTS Fifty-one percent of patients harbored KRAS mutations; 15% had PIK3CA mutations. In… CONTINUE READING